Drug Trial Radar · NCT07424547
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
386
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Dec 2029
Study completion Apr 2030
Sponsor
- Lead sponsor
- Conjupro Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.
Conditions
- Cancer
- Solid Tumor Cancer
- Advanced Metastatic Cancer
- Prostate
- Small Cell Lung Cancer
- Ovarian Cancer
- Breast Cancer
Interventions
SYS6043Drug
Administered by intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a).Time frame: An average of 1 year.
- Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a)Time frame: An average 1 year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
BRCR Global
Plantation, Florida · Recruiting
Florida Clinical Trials Group
Plantation, Florida · Recruiting
NEXT Oncology Austin
Austin, Texas · Recruiting
NEXT Oncology San Antonio
San Antonio, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.